Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Recruiting Phase 2 Phase 3 Interventional Study
Recurrent Ovarian Cancer Signal Transduction Pathway Deregulation Therapy-Associated Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
148 (estimated)
Sponsor
Gynaecologisch Oncologisch Centrum Zuid · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed be…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Female, age \> 18 years * Patients with recurrent ovarian cancer who meet one of the following criteria: * Platinum-resistant disease, defined as disease recurrence or progression within six months of last platinum-based chemotherapy or; * Patient refrains from standard therap…
Contacts

Jurgen M Piek, MD, PhD

+31(0)40 239 91 11

jurgen.piek@catharinaziekenhuis.nl

CONTACT

Ruud Bekkers, MD, PhD

+31(0)40 239 91 11

ruud.bekkers@catharinaziekenhuis.nl

CONTACT